Dr. Benjamin Goldenson, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Northwestern University Feinberg Medical School (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 395
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: Northwestern University Feinberg Medical School
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A150833 (first issued 2017; current) -
Internal Medicine Physician
CA license A150833 (first issued 2017; current) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
Medical groups
- Hoag Clinic (460 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 395
- Services billed
- 1,556
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 147 | 100 |
| New patient office or other outpatient visit, 60-74 minutes | 88 | 88 |
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Newport Beach, CA | 85 |
| Hydroxyurea Other prescribers in Newport Beach, CA | 85 |
| Acyclovir Other prescribers in Newport Beach, CA | 70 |
| Prednisone Other prescribers in Newport Beach, CA | 30 |
| Lenalidomide | 28 |
| Venclexta (venetoclax) | 27 |
| Xarelto (rivaroxaban) Other prescribers in Newport Beach, CA | 25 |
| Pomalyst (pomalidomide) | 22 |
| Ondansetron Odt (ondansetron) Other prescribers in Newport Beach, CA | 21 |
| Allopurinol Other prescribers in Newport Beach, CA | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 22 payments worth $9,054 in total to this clinician.
| Geron Corporation | $2,215 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $2,100 |
| Pfizer Inc. | $2,100 |
| Novartis Pharmaceuticals Corporation | $1,650 |
| Janssen Biotech, Inc. | $524 |
| Kite Pharma, Inc. | $207 |
| Alexion Pharmaceuticals, Inc. | $175 |
| Legend Biotech USA Inc. | $40.71 |
| Consulting Fee | $8,105 |
|---|---|
| Food and Beverage | $933 |
| Education | $15.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 10, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 15, 2025 | Consulting Fee | $2,100 |
| Geron Corporation Oct 22, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $2,080 |
| Novartis Pharmaceuticals Corporation Oct 22, 2025 | Consulting Fee | $1,650 |
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $175 |
| Janssen Pharmaceuticals, Inc Aug 19, 2025 | Education in-kind | $15.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $78,826 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
Janssen Research & Development, LLC - A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America, Inc. · Recruiting · NCT04176198
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.